[TENAGA] QoQ Annualized Quarter Result on 30-Jun-2018 [#2]

Announcement Date
30-Aug-2018
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
30-Jun-2018 [#2]
Profit Trend
QoQ- -20.81%
YoY--%
View:
Show?
Annualized Quarter Result
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
Revenue 52,979,200 50,392,500 50,460,933 49,543,800 49,096,000 15,827,100 69,642,000 -18.56%
PBT 8,294,400 5,046,600 6,458,533 7,878,600 9,661,600 2,979,300 13,321,200 -29.94%
Tax -2,209,600 -1,301,600 -1,263,066 -1,108,200 -1,194,400 -235,400 -381,000 274.39%
NP 6,084,800 3,745,000 5,195,466 6,770,400 8,467,200 2,743,900 12,940,200 -43.25%
-
NP to SH 6,227,200 3,723,700 5,144,000 6,714,000 8,478,800 2,755,700 12,910,800 -42.16%
-
Tax Rate 26.64% 25.79% 19.56% 14.07% 12.36% 7.90% 2.86% -
Total Cost 46,894,400 46,647,500 45,265,466 42,773,400 40,628,800 13,083,200 56,701,800 -13.29%
-
Net Worth 57,696,331 57,716,936 57,861,523 58,929,439 57,803,260 57,155,513 59,181,222 -1.89%
Dividend
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
Div - 3,023,068 2,289,568 3,432,716 - 1,212,063 - -
Div Payout % - 81.18% 44.51% 51.13% - 43.98% - -
Equity
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
Net Worth 57,696,331 57,716,936 57,861,523 58,929,439 57,803,260 57,155,513 59,181,222 -1.89%
NOSH 5,686,888 5,686,888 5,678,180 5,678,180 5,665,986 5,665,986 5,665,986 0.27%
Ratio Analysis
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
NP Margin 11.49% 7.43% 10.30% 13.67% 17.25% 17.34% 18.58% -
ROE 10.79% 6.45% 8.89% 11.39% 14.67% 4.82% 21.82% -
Per Share
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
RPS 931.60 887.97 889.51 873.76 866.50 279.57 1,229.12 -18.79%
EPS 109.52 65.62 90.68 118.40 149.64 48.68 227.88 -42.32%
DPS 0.00 53.27 40.36 60.54 0.00 21.41 0.00 -
NAPS 10.1455 10.1704 10.1997 10.3929 10.2018 10.096 10.445 -2.16%
Adjusted Per Share Value based on latest NOSH - 5,678,180
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
RPS 913.92 869.30 870.48 854.66 846.93 273.03 1,201.36 -18.56%
EPS 107.42 64.24 88.74 115.82 146.26 47.54 222.72 -42.16%
DPS 0.00 52.15 39.50 59.22 0.00 20.91 0.00 -
NAPS 9.9529 9.9565 9.9814 10.1656 9.9714 9.8596 10.2091 -1.89%
Price Multiplier on Financial Quarter End Date
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
Date 29/03/19 31/12/18 28/09/18 29/06/18 30/03/18 29/12/17 30/11/17 -
Price 12.66 13.60 15.46 14.64 16.24 15.26 15.46 -
P/RPS 1.36 1.53 1.74 1.68 1.87 5.46 1.26 5.90%
P/EPS 11.56 20.73 17.05 12.36 10.85 31.35 6.78 49.29%
EY 8.65 4.82 5.87 8.09 9.21 3.19 14.74 -32.98%
DY 0.00 3.92 2.61 4.14 0.00 1.40 0.00 -
P/NAPS 1.25 1.34 1.52 1.41 1.59 1.51 1.48 -11.91%
Price Multiplier on Announcement Date
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/11/17 CAGR
Date 28/05/19 28/02/19 27/11/18 30/08/18 25/05/18 28/02/18 26/01/18 -
Price 11.66 13.42 14.72 15.68 15.04 15.70 15.84 -
P/RPS 1.25 1.51 1.65 1.79 1.74 5.62 1.29 -2.33%
P/EPS 10.65 20.45 16.23 13.24 10.05 32.25 6.95 37.78%
EY 9.39 4.89 6.16 7.55 9.95 3.10 14.39 -27.42%
DY 0.00 3.97 2.74 3.86 0.00 1.36 0.00 -
P/NAPS 1.15 1.32 1.44 1.51 1.47 1.56 1.52 -18.90%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment